
Miriam Grazia Ferrara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4157019/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas. Expert Review of Anticancer Therapy, 2022, 22, 785-794.	1.1	3
2	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT― study. Cancer Immunology, Immunotherapy, 2021, 70, 1583-1592.	2.0	12
3	Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentreÂreal-world study. European Journal of Cancer, 2021, 148, 24-35.	1.3	19
4	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. Journal of Molecular Pathology, 2021, 2, 207-222.	0.5	0
5	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2021, 22, 351-360.	1.1	7
6	Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned. Cells, 2021, 10, 2685.	1.8	4
7	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. Cancers, 2020, 12, 1196.	1.7	65
8	Long-term survivors with immunotherapy in advanced NSCLC: is â€~cure' within reach?. Translational Cancer Research, 2020, 9, 409-414.	0.4	3
9	Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine. Translational Lung Cancer Research, 2018, 7, S312-S317.	1.3	1